Berres Brothers Coffee Roasters Lunch with Elvis decaffeinated ground coffee packaged in 12 oz. (340g) bags with no UPC.
⚠ Critical Alert — Stop Using Immediately
This product has been flagged with severe risks (undeclared allergen). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.
FDA Recall Notice
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0817-2013.
Berres Brothers Coffee Roasters is recalling 3 flavors of regular and decaffeinated, ground and whole bean coffees because they contain undeclared walnut. Chocolate & Peanut Butter, Monkey Mocha, and Lunch with Elvis
Corrective Action (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0817-2013.
Recall terminated by FDA.
✅ What you should do
- Stop using the product if you own it.
- Check the model number, lot code, or sell-by date against the recall notice above.
- Contact Berres Brothers, Inc. or the retailer where you bought it for a refund, replacement, or repair.
- For the most current official instructions, visit the FDA recall page.
- If you've been hurt by this product, report the incident to FDA.
Consumer Contact (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0817-2013.
Berres Brothers, Inc.
About the U.S. Food and Drug Administration
The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.
Visit FDA.gov →📣 Report a food, supplement, or cosmetic problem to the FDA
If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.
Berres Brothers, Inc. Recall FAQ
Berres Brothers, Inc. is the subject of a beverages safety report: Berres Brothers Coffee Roasters Lunch with Elvis decaffeinated ground coffee packaged in 12 oz. (340g) bags with no UPC.. The notice was published on November 14, 2012 by the U.S. Food and Drug Administration (FDA). Approximately 10 units are potentially affected.